Skip to main content

Table 4 Response (ITT population)

From: Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

  LD 5-FU (n = 7) HD 5-FU (n = 45) Total (n = 52)
Response rate (%)    
   Best overall response rate [95% CI]a 57
[18, 90]
47
[32, 62]
48
[34, 62]
   Stable disease 29 40 39
   Progressive disease 14 9 10
   Not assessable 0 4 4
Disease control rate (CR + PR + SD) (%) [95% CI] 86
[42, 100]
87
[73, 95]
87
[74, 94]
Median duration of response, days [95% CI] 7.7
[2.9, 12.2]
9.9
[8.1, 13.6]
9.9
[8.1, 11.4]
  1. aAll partial responses. LD = low-dose 5-FU; HD = high-dose 5-FU; CI = confidence intervals; CR = complete response; PR = partial response; SD = stable disease